Last Updated on: 13th September 2025, 07:13 pm
Upperton Pharma Solutions has secured another prestigious accolade, winning Pharma Contract Services Company of the Year at the Pharma Industry Awards UK 2025. The Nottingham-based company was also shortlisted for Pharma Company of the Year, adding to its track record of recognition after winning Large Pharma Project of the Year in 2024.
Now in its third edition, the Pharma Industry Awards UK are among the most respected events in the sector. Recognising the global significance of the UK pharmaceutical industry, the awards are judged by an independent panel of experts from both academia and industry. Entrants are assessed on innovation, strategy, and demonstrable impact across client projects.
For Upperton, this year’s victory is particularly significant. The CDMO has developed a strong reputation for partnering with small and mid-sized biotech businesses worldwide, offering services that span from pre-clinical development through to late-stage manufacturing across oral, nasal, pulmonary, and parenteral dosage forms.
Nikki Whitfield, Chief Executive Officer of Upperton Pharma Solutions, said:
“Winning the Pharma Contract Services of the Year is an incredible recognition of our team’s hard work and dedication. This award reflects the trust our clients place in us and our commitment to delivering science-led solutions that help bring medicines to patients faster.”
Industry observers regard Upperton’s win this year as an important milestone, with categories fiercely contested amongst leading names in pharma. Upperton winning the award for Contract Services Company of the Year builds on the success at the 2024 Pharma Industry Awards UK, where Upperton won Large Pharma Project of the Year for the build of a 50,000 sq. ft development and manufacturing facility, Trent Gateway.
The recognition also comes at a time of expansion in the CDMO market, driven by demand for personalised medicines. With more biotechs seeking agile partners to accelerate novel therapies, Upperton’s reputation for expertise and adaptability has established it as a trusted name both in the UK and internationally.
Richard Johnson, Chief Scientific Officer at Upperton, said 2025 represents an exciting period for the organisation. The company is preparing to complete its new sterile facility and has secured funding to develop an oral formulation for Adenovirus-vectored vaccines in collaboration with the University of Oxford’s Pandemic Sciences Institute.
Operating from a 60,000 sq. ft state-of-the-art facility in Nottingham, Upperton Pharma Solutions provides comprehensive CDMO services, including formulation development, clinical trial manufacturing, and production across a broad range of dosage forms such as oral solids, liquids, inhalation products, semi-solids, and sterile medicines.
